JP2010538062A - 徐放性アジスロマイシン固形製剤 - Google Patents

徐放性アジスロマイシン固形製剤 Download PDF

Info

Publication number
JP2010538062A
JP2010538062A JP2010523991A JP2010523991A JP2010538062A JP 2010538062 A JP2010538062 A JP 2010538062A JP 2010523991 A JP2010523991 A JP 2010523991A JP 2010523991 A JP2010523991 A JP 2010523991A JP 2010538062 A JP2010538062 A JP 2010538062A
Authority
JP
Japan
Prior art keywords
azithromycin
sustained
formulation
release solid
solid oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
JP2010523991A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010538062A5 (enExample
Inventor
ピライ、ラドハクリシナン
サーポットダー、プラモド
オスボーン、デービッド、ダブリュー．
ドウ、ゴードン、ジェイ．
Original Assignee
ドウ ファーマシューティカル サイエンシーズ、インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドウ ファーマシューティカル サイエンシーズ、インク． filed Critical ドウ ファーマシューティカル サイエンシーズ、インク．
Publication of JP2010538062A publication Critical patent/JP2010538062A/ja
Publication of JP2010538062A5 publication Critical patent/JP2010538062A5/ja
Revoked legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2010523991A 2007-09-05 2008-07-30 徐放性アジスロマイシン固形製剤 Revoked JP2010538062A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96750407P 2007-09-05 2007-09-05
US12/002,417 US8124123B2 (en) 2007-09-05 2007-12-17 Controlled release azithromycin solid dosages forms
PCT/US2008/009169 WO2009032037A1 (en) 2007-09-05 2008-07-30 Controlled release azithromycin solid dosages forms

Publications (2)

Publication Number Publication Date
JP2010538062A true JP2010538062A (ja) 2010-12-09
JP2010538062A5 JP2010538062A5 (enExample) 2011-09-15

Family

ID=40407900

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010523991A Revoked JP2010538062A (ja) 2007-09-05 2008-07-30 徐放性アジスロマイシン固形製剤
JP2010524023A Withdrawn JP2010538066A (ja) 2007-09-05 2008-09-04 皮膚疾患治療用アジスロマイシン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010524023A Withdrawn JP2010538066A (ja) 2007-09-05 2008-09-04 皮膚疾患治療用アジスロマイシン

Country Status (12)

Country Link
US (2) US8124123B2 (enExample)
EP (2) EP2197420A4 (enExample)
JP (2) JP2010538062A (enExample)
KR (2) KR20100063088A (enExample)
CN (2) CN101861138A (enExample)
AR (1) AR068368A1 (enExample)
AU (2) AU2008295579A1 (enExample)
BR (1) BRPI0816268A2 (enExample)
CA (2) CA2697496A1 (enExample)
RU (2) RU2010109358A (enExample)
WO (2) WO2009032037A1 (enExample)
ZA (2) ZA201001649B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003299659A1 (en) 2002-12-13 2004-07-09 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
EP2219622A1 (en) 2007-12-06 2010-08-25 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
AU2014233453A1 (en) 2013-03-15 2015-10-01 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
CN109475505A (zh) 2016-07-06 2019-03-15 度瑞公司 具有药物组成物、屏障层及药物层的口服剂型
NZ752894A (en) * 2016-10-06 2023-05-26 Orbus Therapeutics Inc Formulations for administration of eflornithine
CN109875970B (zh) * 2019-01-08 2021-08-06 石家庄四药有限公司 阿奇霉素固体制剂及其制备方法
CN113116859B (zh) * 2021-04-12 2022-08-30 海南普利制药股份有限公司 阿奇霉素丸芯包衣制剂
WO2023283427A2 (en) * 2021-07-09 2023-01-12 Verdure Biotech, Inc. Enteric and delayed release formulations of locally bioavailable drugs (lbd) targeting the colon

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07300420A (ja) * 1994-04-29 1995-11-14 Pfizer Inc アジスロマイシン投与法
JPH09505609A (ja) * 1994-05-06 1997-06-03 ファイザー・インコーポレーテッド アジスロマイシンの放出調節された剤形
JP2001507359A (ja) * 1997-01-03 2001-06-05 エラン コーポレーション ピーエルシー 徐放性シサプリドミニ錠剤製剤
JP2006510666A (ja) * 2002-12-09 2006-03-30 サルヴォナ エルエルシー ｐＨトリガ標的制御放出デリバリーシステム
WO2006135480A2 (en) * 2005-04-08 2006-12-21 Abbott Laboratories Oral pharmaceutical formulations comprising fenofibric acid and/or its salts
JP2007504102A (ja) * 2003-08-29 2007-03-01 ライフサイクル ファーマ アクティーゼルスカブ タクロリムスを含む改質放出組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
US6368628B1 (en) * 2000-05-26 2002-04-09 Pharma Pass Llc Sustained release pharmaceutical composition free of food effect
US20050239723A1 (en) * 2004-04-27 2005-10-27 Amin Avinash N Compositions and methods useful for treatment of acne
CA2591923A1 (en) 2004-12-21 2006-06-29 Pfizer Products Inc. Enteric coated azithromycin multiparticulates
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
WO2007086978A2 (en) * 2005-11-09 2007-08-02 Dow Pharmaceutical Sciences Azithromycin for treatment of granulomatous rosacea
US7704959B2 (en) * 2006-10-03 2010-04-27 Dow Pharmaceutical Sciences Azithromycin for the treatment of nodular acne

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07300420A (ja) * 1994-04-29 1995-11-14 Pfizer Inc アジスロマイシン投与法
JPH09505609A (ja) * 1994-05-06 1997-06-03 ファイザー・インコーポレーテッド アジスロマイシンの放出調節された剤形
JP2001507359A (ja) * 1997-01-03 2001-06-05 エラン コーポレーション ピーエルシー 徐放性シサプリドミニ錠剤製剤
JP2006510666A (ja) * 2002-12-09 2006-03-30 サルヴォナ エルエルシー ｐＨトリガ標的制御放出デリバリーシステム
JP2007504102A (ja) * 2003-08-29 2007-03-01 ライフサイクル ファーマ アクティーゼルスカブ タクロリムスを含む改質放出組成物
WO2006135480A2 (en) * 2005-04-08 2006-12-21 Abbott Laboratories Oral pharmaceutical formulations comprising fenofibric acid and/or its salts

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6013014430; ＧＡＮＤＨＩ，Ｒ．　ｅｔ　ａｌ: 'Ｐｈａｒｍａｃｏｋｉｎｅｔｉｃ　ｅｖａｌｕａｔｉｏｎ　ｏｆ　ａｎ　ａｚｉｔｈｒｏｍｙｃｉｎ　ｃｏｎｔｒｏｌｌｅｄ　ｒｅｌｅａｓｅ　ｄｏｓａｇｅ　ｆｏｒｍ　ｉｎ　ｈｅａｌｔｈｙ　ｈｕｍａｎ　ｖｏｌｕｎｔ' Ｉｎｔ　Ｊ　Ｐｈａｒｍ Ｖｏｌ．２７０，　Ｎｏ．１-２, 2004, ｐ．１-８ *
JPN7013001132; ＦＥＲＮＡＮＤＥＺ-ＯＢＲＥＧＯＮ，Ａ．Ｃ．: 'Ａｚｉｔｈｒｏｍｙｃｉｎ　ｆｏｒ　ｔｈｅ　ｔｒｅａｔｍｅｎｔ　ｏｆ　ａｃｎｅ' Ｉｎｔ　Ｊ　Ｄｅｒｍａｔｏｌ Ｖｏｌ．３９，　Ｎｏ．１, 2000, ｐ．４５-５０ *

Also Published As

Publication number Publication date
EP2197453A1 (en) 2010-06-23
ZA201001649B (en) 2010-11-24
EP2197420A4 (en) 2010-10-20
CN101835475A (zh) 2010-09-15
KR20100054842A (ko) 2010-05-25
WO2009032037A1 (en) 2009-03-12
EP2197420A1 (en) 2010-06-23
EP2197453A4 (en) 2010-10-20
WO2009032268A1 (en) 2009-03-12
US20090060994A1 (en) 2009-03-05
AU2008296903A1 (en) 2009-03-12
RU2010109359A (ru) 2011-10-20
CA2697537A1 (en) 2009-03-12
AU2008295579A1 (en) 2009-03-12
RU2010109358A (ru) 2011-10-20
AR068368A1 (es) 2009-11-11
ZA201001705B (en) 2010-12-29
JP2010538066A (ja) 2010-12-09
US20120121702A1 (en) 2012-05-17
CN101861138A (zh) 2010-10-13
KR20100063088A (ko) 2010-06-10
BRPI0816268A2 (pt) 2017-08-22
US8124123B2 (en) 2012-02-28
CA2697496A1 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
US20230011269A1 (en) Pharmaceutical composition comprising a potent inhibitor of urat1
EP1098635B1 (en) Enteric coated pharmaceutical tablet containing didanosine
JP2010538062A (ja) 徐放性アジスロマイシン固形製剤
IE53543B1 (en) New oral dipyridamole preparations
GB2414668A (en) Sustained release delivery system for tetracycline compounds
US20080139624A1 (en) Oral Dosage Form Comprising Rosiglitazone
US20070243249A1 (en) Novel formulation of pyridoxal-5'-phosphate and method of preparation
TWI883162B (zh) 一種非布司他片
US20160045442A1 (en) Stable pharmaceutical compositions of mesalamine
WO2020104955A1 (en) Pharmaceutical compositions of acotiamide and proton pump inhibitor
RU2820820C2 (ru) Фармацевтические композиции акотиамида и ингибитора протонной помпы
WO2022070209A1 (en) Biphasic release fixed dose combination formulations
MXPA00011974A (en) Enteric coated pharmaceutical tablet and method of manufacturing
HK1104791B (en) Dipyridamole extended-release formulations and process for preparing same
HK1104791A1 (en) Dipyridamole extended-release formulations and process for preparing same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110726

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110726

AA91 Notification that invitation to amend document was cancelled

Free format text: JAPANESE INTERMEDIATE CODE: A971091

Effective date: 20110816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130402

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130903